REMARKS

Before entry of the present amendment Claims 1, 3, 4, 7 and 8 were pending. Claims 1, 3, 4, 7 and 8 are hereby canceled and new Claims 9 – 19 are added. Applicants have withdrawn new Claims 17-19. After entry of the present amendment, new Claims 9 – 16 will be pending.

Applicants had inadvertently and without deceptive intent submitted an incorrect preliminary amendment in the present case on December 19, 2005. Applicants have now corrected this preliminary amendment by canceling those Claims and adding new Claims 9 – 19. Support for new Claims 9 – 19 is found in the originally filed Claims before entry of the preliminary amendment.

Applicants propose the restricting the new Claims 9 - 19 into four Groups:

I.   Claims 9 - 16 drawn to a compound of formula (I).

II. Claim 17 drawn to a pharmaceutical composition comprising a compound of formula (I).

III. Claim 18 drawn to a method of treatment with formula (I).

IV. Claim 19 drawn to a process for preparing a compound of formula (I).

Applicants hereby elect to prosecute the subject matter assigned to proposed Group I {*i.e.*, Claims 9 - 16}, without traverse. Applicants expressly reserve the right to pursue the subject matter of the non-elected claims that have been assigned to groups II, III and IV in one or more divisional application(s).

Applicants herein elect to prosecute the species found in Example 1 of the Application as follows:

Claims 9 - 16 read on this elected species.

CONCLUSION

Accordingly, Applicant respectfully requests that the Examiner enters the present response to the Restriction Requirement according to the election selected from the grouping presented above.

Respectfully submitted,

_____
R. Steve Thomas
Attorney for Applicants
Registration No. 52,284

Date: _____
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8406
Facsimile: (919) 483-7988